[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640423":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":33,"centralContacts":40,"locations":46,"responsibleParty":61,"collaborators":11,"id":63,"slug":11,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":11,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":11,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":11,"overallStatus":81,"whyStopped":11,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Shanghai Jeyou Pharmaceutical Co., Ltd.","INDUSTRY",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"JMKX000189 Dose 1","EXPERIMENTAL",null,[13],"Drug: JMKX000189",{"label":15,"type":10,"description":11,"interventionNames":16},"JMKX000189 Dose 2",[13],{"label":18,"type":19,"description":11,"interventionNames":20},"placebo","PLACEBO_COMPARATOR",[21],"Other: Placebo",[23,28],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"DRUG","JMKX000189","JMKX000189 administered orally.",[9,15],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"OTHER","Placebo","Placebo administered orally.",[18],[34,38],{"name":35,"affiliation":36,"role":37},"Ruofan Huang","Huashan Hospital","PRINCIPAL_INVESTIGATOR",{"name":39,"affiliation":36,"role":37},"Xiaojie Wu",[41],{"name":42,"role":43,"phone":44,"phoneExt":11,"email":45},"Fawei Wu","CONTACT","+86 15720614080","wufawei@jeyoupharma.com",[47],{"facility":48,"status":11,"city":49,"state":11,"zip":11,"country":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Huashan Hospital Fudan University","Shanghai","China",{"type":52,"coordinates":53},"Point",[54,55],121.45806,31.22222,{"lat":55,"lon":54},[58],{"name":35,"role":43,"phone":59,"phoneExt":11,"email":60},"(+86)021-52888045","ruofanhuang@fudan.edu.cn",{"type":62,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100640423",false,"NCT07601386","Safety and Efficacy of JMKX000189 for Chemotherapy-Induced Peripheral Neuropathy","A Phase Ib Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of JMKX000189 Tablets in Patients With Chemotherapy-Induced Peripheral Neuropathy","Inclusion Criteria:\n\n* Aged 18 to 75 years (inclusive), male or female.\n* Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2.\n* Life expectancy of ≥ 3 months.\n* Histologically or cytologically confirmed malignant solid tumors.\n* Investigator-confirmed diagnosis of CIPN accompanied with chemotherapy.\n* Adequate organ function.\n\nExclusion Criteria:\n\n* Presence of any type of peripheral neuropathy other than CIPN (e.g., diabetic, paraneoplastic, or nutritional).\n* Toxicities from prior anti-tumor therapy (excluding CIPN) \\> CTCAE Grade 1 within 2 weeks of first dose (excluding alopecia, skin pigmentation, stable hypothyroidism, or chronic events).\n* Participants with any of the following cardiovascular diseases or medical history:\n\n  1. Ischemic heart disease or myocardial infarction, unstable angina, coronary artery spasm, congestive heart failure (NYHA Class III-IV), cardiac arrest, stroke, or transient ischemic attack within 6 months;\n  2. Other clinically significant cardiac disorders per investigator's judgment.\n* Presence of active systemic infections.\n* History of or active primary\u002Fsecondary immunodeficiency.\n* Participation in an interventional clinical trial within 1 month prior to screening.\n* Hypersensitivity to any component of the study drug (and its excipients).\n* Any condition deemed by the investigator to pose excessive risk, confound results, or interfere with compliance.","ALL","18 Years","75 Years",{"count":73,"type":74},18,"ESTIMATED","INTERVENTIONAL",[77],"PHASE1","This Phase Ib clinical trial aims to evaluate the safety, tolerability, and preliminary efficacy of JMKX000189 tablets in participants with chemotherapy-induced peripheral neuropathy (CIPN).",[80],"CIPN - Chemotherapy-Induced Peripheral Neuropathy","NOT_YET_RECRUITING","2026-05-15",{"date":84,"type":85},"2026-05-22","ACTUAL",{"date":87,"type":74},"2026-05-10",{"date":89,"type":74},"2027-06-20",{"name":5,"class":6},1]